Singaporean-based cancer diagnostics company X-ZELL has announced that it will open a new international office in Sauerland, Nordrhein-Westfalen, as a launchpad for its foray into the European diagnostics market.
X-ZELL has developed a platform technology capable of identifying ultra-rare cancer cells in a 10ml blood sample and analysing them using artificial intelligence.
“It is with great pleasure that we are finally able to announce the opening of X-ZELL Europe, and I couldn’t be more excited for it to take place where my personal journey began too,” said founder and chief executive Sebastian Bhakdi, who was born in Germany and received his medical doctorate from the University of Freiburg before emigrating to Southeast Asia.
“Home to one of the largest statutory health insurance systems in the world, Germany is quickly evolving into a central hub for innovative health technology,” he explained. “By establishing an office here we hope to be able to become part of that evolution and bring a new perspective on AI-powered early cancer detection to the European healthcare market.”
X-ZELL said that its initial focus will be on engineering and product development, as well as engaging with Europe’s rare cell research and cyto-pathology community.
The company closed an oversubscribed Seed+ round of US$4m led by German industrial service group, Deutsche Industrieanlagen (DIAG) in October.